Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists uncover clue to leg artery disease in MicroRNA

NCT ID NCT04089943

Completed Knowledge-focused Sponsor: University of West Florida Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at a molecule called microRNA-210 in 230 people with peripheral artery disease (PAD), a condition where leg arteries become blocked. Researchers measured its levels and linked them to oxidative stress and walking ability. The goal was to understand how this molecule might be used as a target for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this research could point toward new treatments for peripheral artery disease by targeting microRNA-210 to improve walking and quality of life.
What could go wrong
This is a completed observational study, not a treatment trial. The findings may not directly lead to therapies, and further research is needed to confirm any benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIAL OCCLUSIVE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arterial Occlusive Diseases atherosclerosis limb ischemia peripheral arterial disease peripheral vascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTERIAL OCCLUSIVE DISEASES ATHEROSCLEROSIS PERIPHERAL ARTERIAL DISEASE VASCULAR DISEASES, PERIPHERAL

Contacts and locations

Locations

  • Baylor Scott and White

    Temple, Texas, 76508, United States

  • UT Austing Dell Medical School

    Austin, Texas, 78712, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.